1
|
Li J, Jiang Z. Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects. Cancer 2024; 130:1371-1377. [PMID: 37921976 DOI: 10.1002/cncr.35093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 10/03/2023] [Accepted: 10/10/2023] [Indexed: 11/05/2023]
Abstract
Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against tumor cells. China approved T-Dxd in May 2023, and their introduction has changed the nation's clinical practice. Although more than 700 ADCs are being investigated worldwide, the challenges that remain in antibody engineering, drug discovery, safety management, resistance, drug selection, and sequencing hinder the further promotion and application of ADCs. Experts in China have discussed the several critical concerns related to clinical practice since 2022. Here, the authors conducted a review of ADCs and then discussed several ADCs explored in China. This study proposes several solutions and strategies to maximize the potential benefit that ADCs can provide to patients with breast cancer.
Collapse
Affiliation(s)
- Jianbin Li
- Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China
- Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China
| | - Zefei Jiang
- Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China
| |
Collapse
|
2
|
Gao Y, Yang Y, Li X, Wang T, Cheng Q, Jia Z, Niu SX, Zhang XY, Wang BJ, Zhang X. Vesicoprostatic muscle reconstruction: a step further for immediate and early urinary continence. World J Urol 2023:10.1007/s00345-023-04398-9. [PMID: 37093318 DOI: 10.1007/s00345-023-04398-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 04/01/2023] [Indexed: 04/25/2023] Open
Abstract
OBJECTIVES The vesicoprostatic muscle (VPM) is a longitudinal smooth muscle that originates from the trigone of the bladder or the opening of the ureter and is involved in urination as part of the detrusor apron. We explored the effect of VPM reconstruction on immediate and early recovery of urinary continence in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). PATIENTS AND METHODS A total of 523 patients with localized prostate cancer were enrolled from June 2018 to June 2020. All patients were diagnosed in our department based on magnetic resonance imaging and pathological findings on prostate biopsy. After 1:1 propensity score matching, 105 patient pairs were matched. The study was approved by our institutional review board and all surgeries were performed by three experienced high-volume surgeons. Demographic data, total operation time, pathological outcomes, the urinary continence rates of the two groups at different times after RALP, and factors influencing postoperative urinary continence after RALP were recorded. Student's t test was used to compare continuous variables and the Pearson χ2 test to compare categorical variables. Logistic regression analysis was used to identify factors affecting immediate and early postoperative urinary control. RESULTS VPM reconstruction promoted immediate and early recovery of urinary continence (immediate continence, 66.67 vs. 40.00%, P = 0.000; 3-month continence, 80.95 vs. 64.76%, P = 0.008). CONCLUSIONS VPM reconstruction improved immediate and early urinary continence in patients who underwent RALP.
Collapse
Affiliation(s)
- Yu Gao
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Yang Yang
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
- Medical School of Chinese PLA, Beijing, People's Republic of China
| | - Xing Li
- Department of Urology, China Rehabilitation Research Centre, Rehabilitation School of Capital Medical University, Beijing, People's Republic of China
| | - Tao Wang
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
- Medical School of Chinese PLA, Beijing, People's Republic of China
| | - Qiang Cheng
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Zhuo Jia
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Shao-Xi Niu
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Xiang-Yi Zhang
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Bao-Jun Wang
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China.
- Department of Urology, PLA Military General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China.
| | - Xu Zhang
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China.
- Department of Urology, PLA Military General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China.
| |
Collapse
|